Open AccessLamotrigina y su relación con el síndrome de Stevens-Johnson y la necrólisis epidérmica tóxica
Author(s) -
Eduardo Alexis Velázquez-Cárcamo,
Yuriria Rodríguez-Chávez,
Silvia MéndezFlores,
Judith DomínguezCherit
Publication year - 2021
Publication title -
revista medica del instituto mexicano del seguro social/revista médica del instituto mexicano del seguro social
Language(s) - Spanish
Resource type - Journals
eISSN - 2448-5667
pISSN - 0443-5117
DOI - 10.24875/rmimss.m20000018
Subject(s) - lamotrigine , toxic epidermal necrolysis , medicine , dermatology , epilepsy , epileptic spasms , adverse effect , food and drug administration , anticonvulsant , psychiatry , pharmacology
Lamotrigine is an antiepileptic drug that has been widely used for epilepsy, as a mood stabilizer (for type 1 bipolar disorder) and in the management of neuropathic pain, it is used both in monotherapy and in complementary therapy. Considered relatively new, approved by the Food and Drug Administration in 1994, its benefits include a greater margin of safety compared to other anticonvulsants. However, although in a lower percentage, it causes severe adverse skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis. A review is made about the probable pathways that trigger this delayed hypersensitivity immune response.